Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4508-4514

  El Galaly, Tarec Christoffer ^a,c   D'Amore, Francesco ^c   Mylam, Karen Juul ^d   Brown, Peter De Nully ^e   Bøgsted, Martin ^a,b   Bukh, Anne ^c   Specht, Lena ^e   Loft, Annika ^e   Iyer, Victor ^a   Hjorthaug, Karin ^c   Nielsen, Anne Lerberg ^d   Christiansen, Ilse ^a   Madsen, Charlotte ^c   Johnsen, Hans Erik ^a   Hutchings, Martin ^e  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE LESION; BONE MARROW BIOPSY; BONE MARROW DISEASE; CANCER PROGNOSIS; CANCER STAGING; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; YOUNG ADULT;

EID: 84871798380     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.4036     Document Type: Article

References (42)

1. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with earlystage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
2. Eich HT, Diehl V, Görgen H, et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206, 2010
3. Engert A, Diehl V, Franklin J, et al: Escalateddose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548-4554, 2009
4. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861, 1971
5. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
6. Munker R, Hasenclever D, Brosteanu O, et al: Bone marrow involvement in Hodgkin's disease: An analysis of 135 consecutive cases - German Hodgkin's Lymphoma Study Group. J Clin Oncol 13:403-409, 1995
7. Levis A, Pietrasanta D, Godio L, et al: A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. Clin Lymphoma 5:50-55, 2004
8. Hines-Thomas MR, Howard SC, Hudson MM, et al: Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma. Haematologica 95:1691-1696, 2010
9. Cavalieri E, Anselmo AP, Gianfelici V, et al: Is bone marrow trephine biopsy always mandatory in staging Hodgkin's disease? Haematologica 90:134-136, 2005
10. Rosenberg SA: Hodgkin's disease of the bone marrow. Cancer Res 31:1733-1736, 1971
11. Howell SJ, Grey M, Chang J, et al: The value of bone marrow examination in the staging of Hodgkin's lymphoma: A review of 955 cases seen in a regional cancer centre. Br J Haematol 119:408-411, 2002
12. Brunning RD, Bloomfield CD, McKenna RW, et al: Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med 82:365-366, 1975
13. Luoni M, Fava S, Declich P: Bone marrow biopsy for staging Hodgkin's lymphoma: The value of bilateral or unilateral trephine biopsy. J Clin Oncol 14:682-683, 1996
14. Engert A, Eichenauer DA, Dreyling M: Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v168-v171, 2010 (suppl 5)
15. Hutchings M, Loft A, Hansen M, et al: Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91:482-489, 2006
16. Gang AO, Strøm C, Pedersen M, et al: R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14: A population-based investigation from the Danish Lymphoma Group. Ann Oncol 23:147-153, 2012
17. Reference deleted
18. Reference deleted
19. Collett D: Modelling Binary Data. Boca Raton, FL, Chapman & Hall/CRC, 1999
20. Reference deleted
21. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
22. Vassilakopoulos TP, Angelopoulou MK, Constantinou N, et al: Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood 105:1875-1880, 2005
23. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
24. Brunetti GA, Tendas A, Meloni E, et al: Pain and anxiety associated with bone marrow aspiration and biopsy: A prospective study on 152 Italian patients with hematological malignancies. Ann Hematol 90:1233-1235, 2011
25. Bain BJ: Morbidity associated with bone marrow aspiration and trephine biopsy: A review of UK data for 2004. Haematologica 91:1293-1294, 2006
26. Carr R, Barrington SF, Madan B, et al: Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91:3340-3346, 1998
27. Moog F, Bangerter M, Kotzerke J, et al: 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603-609, 1998
28. Moulin-Romsee G, Hindié E, Cuenca X, et al: (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 37:1095-1105, 2010
29. Rigacci L, Vitolo U, Nassi L, et al: Positron emission tomography in the staging of patients with Hodgkin's lymphoma: A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86:897-903, 2007
30. Naumann R, Beuthien-Baumann B, Reiss A, et al: Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 90:620-625, 2004
31. Pelosi E, Penna D, Douroukas A, et al: Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: Results from a large multicentre study. Q J Nucl Med Mol Imaging 55:469-475, 2011
32. Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 86:266-273, 2001
33. Elstrom R, Guan L, Baker G, et al: Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875-3876, 2003
34. Purz S, Mauz-Körholz C, Körholz D, et al: [18F] Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 29:3523-3528, 2011
35. Richardson SE, Sudak J, Warbey V, et al: Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era. Leuk Lymphoma 53:381-385, 2012
36. Muzahir S, Mian M, Munir I, et al: Clinical utility of 18F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma. Br J Radiol 85:e490-e496, 2012
37. Pakos EE, Fotopoulos AD, Ioannidis JP: 18FFDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis. J Nucl Med 46:958-963, 2005
38. Hong J, Lee Y, Park Y, et al: Role of FDGPET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol 91:687-695, 2012
39. Zelentz AD, Maragulia J, Horwitz SM: Baseline staging evaluation in lymphoma: The role of FDG PET, CT, and bone marrow biopsy. Blood 118, 2011 (abstr 2640)
40. Sehn LH, Scott DW, Chhanabhai M, et al: Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 29:1452-1457, 2011
41. Schaefer NG, Strobel K, Taverna C, et al: Bone involvement in patients with lymphoma: The role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 34:60-67, 2007
42. Salaun PY, Gastinne T, Bodet-Milin C, et al: Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: A reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 36:1813-1821, 2009